Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress

References

• Arruebo M, Vilaboa N, Sáez-Gutierrez B, et al. Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2011;3(3):3279–3330. doi: 10.3390/cancers3033279
   PubMedGoogle Scholar
• Editorial. Advancing cancer therapy. Nat Cancer. 2021;2(3):245–246. doi: 10.1038/s43018-021-00192-x
   PubMedGoogle Scholar
• Liu YP, Zheng CC, Huang YN, et al. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm. 2021;2(3):315–340. doi: 10.1002/mco2.55.
   PubMedGoogle Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1–14. doi: 10.1111/j.1365-2567.2007.02587.x
   PubMed Web of Science ®Google Scholar
• Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345–359. doi: 10.1038/s41568-021-00347-z
   PubMed Web of Science ®Google Scholar
• Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375–388. doi: 10.1038/s41577-020-0285-6
   PubMed Web of Science ®Google Scholar
• Page DB, Postow MA, Callahan MK, et al. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65(1):185–202. doi: 10.1146/annurev-med-092012-112807
   PubMedGoogle Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461. doi: 10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3(9):666–675. doi: 10.1038/nrc1167
   PubMed Web of Science ®Google Scholar
• Sawasdikosol S, Zha RY, Yang BY, et al. HPK1 as a novel target for cancer immunotherapy. Immunol Res. 2012;54(1–3):262–265. doi: 10.1007/s12026-012-8319-1
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–167. doi: 10.1038/nri.2017.108
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi: 10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi: 10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133. doi: 10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs. 2016;30(6):571–584. doi: 10.1007/s40259-016-0204-3
   PubMed Web of Science ®Google Scholar
• Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–5337. doi: 10.1016/j.cell.2021.09.020
   PubMed Web of Science ®Google Scholar
• Wu YR, Yang ZC, Cheng K, et al. Small molecule-based immune modulators for cancer therapy. Acta Pharm Sin B. 2022;12(12):4287–4308. doi: 10.1016/j.apsb.2022.11.007
   PubMed Web of Science ®Google Scholar
• Dhanak D, Edwards JP, Nguyen A, et al. Small-molecule targets in immuno-oncology. Cell Chem Biol. 2017;24(9):1148–1160. doi: 10.1016/j.chembiol.2017.08.019
   PubMed Web of Science ®Google Scholar
• Offringa R, Kötzner L, Huck B, et al. The expanding role for small molecules in immuno-oncology. Nat Rev Drug Discov. 2022;21(11):821–840. doi: 10.1038/s41573-022-00538-9
   PubMed Web of Science ®Google Scholar
• Sitaram P, Uyemura B, Malarkannan S, et al. Beyond the cell surface: targeting intracellular negative regulators to enhance T cell anti-tumor activity. Int J Mol Sci. 2019;20(23):5821. doi: 10.3390/ijms20235821
   PubMed Web of Science ®Google Scholar
• Koretzky GA, Myung PS. Positive and negative regulation of T-cell activation by adaptor proteins. Nat Rev Immunol. 2001;1(2):95–107. doi: 10.1038/35100523
   PubMed Web of Science ®Google Scholar
• Si JW, Shi XJ, Sun SH, et al. Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies. Cancer Cell. 2020;38(4):551–566. doi: 10.1016/j.ccell.2020.08.001
   PubMed Web of Science ®Google Scholar
• Han Y, Zhu L, Wu W, et al. The expanding role for small molecules in immuno-oncology. Adv Exp Med Biol. 2020;1248:547–618.
   PubMedGoogle Scholar
• Hernandez S, Qing J, Thibodeau RH, et al. The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function. Cell Rep. 2018;25(1):80–94. doi: 10.1016/j.celrep.2018.09.012
   PubMed Web of Science ®Google Scholar
• Linney ID, Kaila N. Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020). Expert Opin Ther Pat. 2021;31(10):893–910. doi: 10.1080/13543776.2021.1924671
   PubMed Web of Science ®Google Scholar
• Wu P, Sneeringer CJ, Pitts KE, et al. Hematopoietic progenitor kinase-1 structure in a domain-swapped dimer. Structure. 2019;27(1):125–133. doi: 10.1016/j.str.2018.10.025
   PubMed Web of Science ®Google Scholar
• Chan BK, Seward E, Lainchbury M, et al. Discovery of spiro-azaindoline inhibitors of hematopoietic progenitor kinase 1 (HPK1). ACS Med Chem Lett. 2021;13(1):84–91. doi: 10.1021/acsmedchemlett.1c00473
   PubMed Web of Science ®Google Scholar
• Johnson E, McTigue M, Gallego RA, et al. Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation. J Biol Chem. 2019;294(23):9029–9036. doi: 10.1074/jbc.AC119.007466
   PubMed Web of Science ®Google Scholar
• Gallego RA, Bernier L, Chen H, et al. Design and synthesis of functionally active 5-amino-6-aryl pyrrolopyrimidine inhibitors of hematopoietic progenitor kinase 1. J Med Chem. 2023;66(7):4888–4909. doi: 10.1021/acs.jmedchem.2c02038
   PubMed Web of Science ®Google Scholar
• Yu EC, Methot JL, Fradera X, et al. Identification of potent reverse indazole inhibitors for HPK1. ACS Med Chem Lett. 2021;12(3):459–466. doi: 10.1021/acsmedchemlett.0c00672
   PubMed Web of Science ®Google Scholar
• Vara BA, Levi SM, Achab A, et al. Discovery of diaminopyrimidine carboxamide HPK1 inhibitors as preclinical immunotherapy tool compounds. ACS Med Chem Lett. 2021;12(4):653–661. doi: 10.1021/acsmedchemlett.1c00096
   PubMed Web of Science ®Google Scholar
• Degnan AP, Kumi GK, Allard CW, et al. Discovery of orally active isofuranones as potent, selective inhibitors of hematopoetic progenitor kinase 1. ACS Med Chem Lett. 2021;12(3):443–450. doi: 10.1021/acsmedchemlett.0c00660
   PubMed Web of Science ®Google Scholar
• Malchow S, Korepanova A, Panchal SC. The HPK1 inhibitor A-745 verifies the potential of modulating T cell kinase signaling for immunotherapy. ACS Chem Biol. 2022;17(3):556–566. doi: 10.1021/acschembio.1c00819
   PubMed Web of Science ®Google Scholar
• Wang MS, Wang ZZ, Li ZL, et al. Discovery of macrocycle-based HPK1 inhibitors for T-cell-based immunotherapy. J Med Chem. 2023;66(1):611–626. doi: 10.1021/acs.jmedchem.2c01551
   PubMed Web of Science ®Google Scholar
• You D, Hillerman S, Locke G, et al. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor. J Immunother Cancer. 2021;9(1):e001402. doi: 10.1136/jitc-2020-001402
   PubMed Web of Science ®Google Scholar
• Ge HZ, Peng LZ, Sun Z, et al. Discovery of novel HPK1 inhibitors through structure-based virtual screening. Front Pharmacol. 2022;13:850855. doi: 10.3389/fphar.2022.850855
   PubMed Web of Science ®Google Scholar
• Shi HY, Tang HT, Li Y, et al. Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors. Eur J Med Chem. 2023;248:115064. doi: 10.1016/j.ejmech.2022.115064
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang K, Georgiev P, et al. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. PLOS ONE. 2020;15(12):e0243145. doi: 10.1371/journal.pone.0243145
   PubMed Web of Science ®Google Scholar
• Sokolsky A, Vechorkin O, Hummel JR, et al. Potent and selective biaryl amide inhibitors of hematopoietic progenitor kinase 1 (HPK1). ACS Med Chem Lett. 2022;14(1):116–122. doi: 10.1021/acsmedchemlett.2c00241
   PubMed Web of Science ®Google Scholar
• Ye QD, Liu K, Ye HF, et al. Discovery of pyrazolopyridine derivatives as HPK1 inhibitors. ACS Med Chem Lett. 2022;14(1):5–10. doi: 10.1021/acsmedchemlett.2c00238
   PubMed Web of Science ®Google Scholar
• Zhou LX, Ye XQ, Wang KZ, et al. Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1. Bioorg Chem. 2023;138:106682. doi: 10.1016/j.bioorg.2023.106682
   PubMed Web of Science ®Google Scholar
• Toure M, Johnson T, Li B, et al. Discovery of quinazoline HPK1 inhibitors with high cellular potency. Bioorg Med Chem. 2023;92:117423. doi: 10.1016/j.bmc.2023.117423
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Li Y, Tang HT, et al. Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors. Bioorg Chem. 2023;20:106811. doi: 10.1016/j.bioorg.2023.106811
   Google Scholar
• Wu FF, Li HY, An Q, et al. Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors. Eur J Med Chem. 2023;254:115355. doi: 10.1016/j.ejmech.2023.115355
   PubMed Web of Science ®Google Scholar
• Lacey BM, Xu ZW, Chai XM, et al. Development of high-throughput assays for evaluation of hematopoietic progenitor kinase 1 inhibitors. SLAS Discov. 2021;26(1):88–99. doi: 10.1177/2472555220952071
   PubMed Web of Science ®Google Scholar
• Wang WX, Mevellec L, Liu A, et al. Discovery of an allosteric, inactive conformation-selective inhibitor of full-length HPK1 utilizing a kinase cascade assay. Biochemistry. 2021;60(41):3114–3124. doi: 10.1021/acs.biochem.1c00486
   PubMed Web of Science ®Google Scholar
• Zhou LX, Wang TY, Zhang KJ, et al. The development of small-molecule inhibitors targeting HPK1. Eur J Med Chem. 2022;244:114819. doi: 10.1016/j.ejmech.2022.114819
   PubMed Web of Science ®Google Scholar
• Setsu G, Goto M, Ito K, et al. Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models. Eur J Pharmacol. 2023;961:176184. doi: 10.1016/j.ejphar.2023.176184
   PubMed Web of Science ®Google Scholar
• Zeng SX, Jin YY, Xia HY, et al. Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling. Bioorg Chem. 2024;143:107016. doi: 10.1016/j.bioorg.2023.107016.
   PubMed Web of Science ®Google Scholar
• Chuang HC, Wang XH, Tan TH. MAP4K family kinases in immunity and inflammation. Adv Immunol. 2016;129:277–314.
   PubMed Web of Science ®Google Scholar
• Sawasdikosol S, Burakoff S. A perspective on HPK1 as a novel immuno-oncology drug target. Elife. 2020;9:e55122. doi: 10.7554/eLife.55122
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ding S, Zhang HL. Interactions between hematopoietic progenitor kinase 1 and its adaptor proteins (review). Mol Med Rep. 2017;16(5):6472–6482. doi: 10.3892/mmr.2017.7494
   PubMed Web of Science ®Google Scholar
• Kiefer F, Tibbles LA, Anafi M. HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway. Embo J. 1996;15(24):7013–7125. doi: 10.1002/j.1460-2075.1996.tb01093.x
   PubMed Web of Science ®Google Scholar
• Boomer JS, Tan TH. Functional interactions of HPK1 with adaptor proteins. J Cell Biochem. 2005;95(1):34–44. doi: 10.1002/jcb.20401
   PubMed Web of Science ®Google Scholar
• Zhu QS, Chen NN, Tian XJ, et al. Hematopoietic progenitor kinase 1 in tumor immunology: a medicinal chemistry perspective. J Med Chem. 2022;65(12):8065–8090. doi: 10.1021/acs.jmedchem.2c00172
   PubMed Web of Science ®Google Scholar
• Wang JJ, Song LJ, Yang S, et al. HPK1 positive expression associated with longer overall survival in patients with estrogen receptor‑positive invasive ductal carcinoma‑not otherwise specified. Mol Med Rep. 2017;16(4):4634–4642. doi: 10.3892/mmr.2017.7131
   PubMed Web of Science ®Google Scholar
• Hu MCT, Wang YP, Qiu WR, et al. Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IκB kinases (IKK-α/β) and IKK-β is a developmentally regulated protein kinase. Oncogene. 1999;18(40):5514–5524. doi: 10.1038/sj.onc.1202740
   PubMed Web of Science ®Google Scholar
• Luehrmann JS, Santner-Nanan B, Jha MK, et al. Hematopoietic progenitor kinase 1 supports apoptosis of T lymphocytes. Blood. 2002;100(3):954–960. doi: 10.1182/blood-2002-01-0089
   PubMed Web of Science ®Google Scholar
• Liu JQ, Curtin J, You D, Mascaux C, et al. Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance. PLOS ONE. 2019;14(3):e0212670. doi: 10.1371/journal.pone.0212670.
   PubMed Web of Science ®Google Scholar
• Hu MC, Qiu WR, Wang X, et al. Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. Genes Dev. 1996;10(18):2251–2264. doi: 10.1101/gad.10.18.2251
   PubMed Web of Science ®Google Scholar
• Kiefer F, Tibbles LA, Anafi M, et al. HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway. Embo J. 1996;15(24):7013–7025. doi: 10.1002/j.1460-2075.1996.tb01093.x
   PubMed Web of Science ®Google Scholar
• Shui JW, Boomer JS, Han J, et al. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responses. Nat Immunol. 2007;8(1):84–91. doi: 10.1038/ni1416
   PubMed Web of Science ®Google Scholar
• Ling P, Yao Z, Meyer CF, et al. Interaction of hematopoietic progenitor kinase 1 with adapter proteins Crk and CrkL leads to synergistic activation of c-Jun N-terminal kinase. Mol Cell Biol. 1999;19(2):1359–1368. doi: 10.1128/MCB.19.2.1359
   PubMed Web of Science ®Google Scholar
• Oehrl W, Kardinal C, Ruf S, et al. The germinal center kinase (GCK)-related protein kinases HPK1 and KHS are candidates for highly selective signal transducers of Crk family adapter proteins. Oncogene. 1998;17(15):1893–1901. doi: 10.1038/sj.onc.1202108
   PubMed Web of Science ®Google Scholar
• Arnold R, Liou J, Drexler HC, et al. Caspase-mediated cleavage of hematopoietic progenitor kinase 1 (HPK1) converts an activator of NFκB into an inhibitor of NFκB. J Biol Chem. 2001;276(18):14675–14684. doi: 10.1074/jbc.M008343200
   PubMed Web of Science ®Google Scholar
• Chen YR, Meyer CF, Ahmed B, et al. Caspase-mediated cleavage and functional changes of hematopoietic progenitor kinase 1 (HPK1. Oncogene. 1999;18(51):7370–7377. doi: 10.1038/sj.onc.1203116
   PubMed Web of Science ®Google Scholar
• Brenner D, Golks A, Becker M, et al. Caspase-cleaved HPK1 induces CD95L-independent activation induced cell death in T and B lymphocytes. Blood. 2007;110(12):3968–3977. doi: 10.1182/blood-2007-01-071167
   PubMed Web of Science ®Google Scholar
• Ling P, Meyer CF, Redmond LP. Involvement of hematopoietic progenitor kinase 1 in T cell receptor signaling. J Biol Chem. 2001;276(22):18908–18914. doi: 10.1074/jbc.M101485200
   PubMed Web of Science ®Google Scholar
• Sauer K, Liou J, Singh SB, et al. Hematopoietic progenitor kinase 1 associates physically and functionally with the adaptor proteins B cell linker protein and SLP76 in lymphocytes. J Biol Chem. 2001;276(48):45207–45216. doi: 10.1074/jbc.M106811200
   PubMed Web of Science ®Google Scholar
• Pombo CM, Kehrl JH, Sánchez I, et al. Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. Nature. 1995;377(6551):750–754. doi: 10.1038/377750a0
   PubMed Web of Science ®Google Scholar
• Diener K, Wang XS, Chen C, et al. Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase. Proc Natl Acad Sci U S A. 1997;94(18):9687–9692. doi: 10.1073/pnas.94.18.9687
   PubMed Web of Science ®Google Scholar
• Su YC, Han JH, Xu SC. NIK is a new Ste20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain. Embo J. 1997;16(6):1279–1290. doi: 10.1093/emboj/16.6.1279
   PubMed Web of Science ®Google Scholar
• Flach RJR, Skoura A, Matevossian A, et al. Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis. Nat Commun. 2015;6(1):8995. doi: 10.1038/ncomms9995
   PubMedGoogle Scholar
• Vitorino P, Yeung S, Crow A, et al. MAP4K4 regulates integrin-FERM binding to control endothelial cell motility. Nature. 2015;519(7544):425–430. doi: 10.1038/nature14323
   PubMed Web of Science ®Google Scholar
• Tung RM, Blenis J. A novel human SPS1/STE20 homologue, KHS, activates Jun N-terminal kinase. Oncogene. 1997;14(6):653–659. doi: 10.1038/sj.onc.1200877
   PubMed Web of Science ®Google Scholar
• Dan I, Watanabe NM, Kobayashi T. Molecular cloning of MINK, a novel member of mammalian GCK family kinases, which is up-regulated during postnatal mouse cerebral development. FEBS Lett. 2000;469(1):19–23. doi: 10.1016/S0014-5793(00)01247-3
   PubMed Web of Science ®Google Scholar
• Fu CA, Shen M, Huang BCB, et al. TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton. J Biol Chem. 1999;274(43):30729–30737. doi: 10.1074/jbc.274.43.30729
   PubMed Web of Science ®Google Scholar
• Jaeger-Ruckstuhl CA, Hinterbrandner M, Höpner S, et al. TNIK signaling imprints CD8+ T cell memory formation early after priming. Nat Commun. 2020;11(1):1632. doi: 10.1038/s41467-020-15413-7
   PubMed Web of Science ®Google Scholar
• Chen DY, Chuang HC, Lan JL, et al. Germinal center kinase-like kinase (GLK/MAP4K3) expression is increased in adult-onset still’s disease and may act as an activity marker. BMC Med. 2012;10(1):84. doi: 10.1186/1741-7015-10-84
   PubMedGoogle Scholar
• Chen YM, Chuang HC, Lin WC, et al. Germinal center kinase-like kinase overexpression in T cells as a novel biomarker in rheumatoid arthritis. Arthritis Rheum. 2013;65(10):2573–2582. doi: 10.1002/art.38067
   PubMedGoogle Scholar
• Chuang HC, Lan JL, Chen DY, et al. The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells. Nat Immunol. 2011;12(11):1113–1118. doi: 10.1038/ni.2121
   PubMed Web of Science ®Google Scholar
• Esen E, Sergin I, Jesudason R, et al. MAP4K4 negatively regulates CD8 T cell–mediated antitumor and antiviral immunity. Sci Immunol. 2020;5(45):2245. doi: 10.1126/sciimmunol.aay2245.
   Web of Science ®Google Scholar
• Liou J, Kiefer F, Dang A, et al. HPK1 is activated by lymphocyte antigen receptors and negatively regulates AP-1. Immunity. 2000;12(4):399–408. doi: 10.1016/S1074-7613(00)80192-2
   PubMed Web of Science ®Google Scholar
• Arnold R, Patzak IM, Neuhaus B, et al. Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1. Mol Cell Biol. 2005;25(6):2364–2383. doi: 10.1128/MCB.25.6.2364-2383.2005
   PubMed Web of Science ®Google Scholar
• Nagata Y, Kiefer F, Watanabe T, et al. Activation of hematopoietic progenitor kinase-1 by erythropoietin. Blood. 1999;93(10):3347–3354. doi: 10.1182/blood.V93.10.3347.410k06_3347_3354
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou G, Hu MC, et al. Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-jun N-terminal kinase (JNK) pathway by transforming growth factor β (TGF-β)-activated kinase (TAK1), a kinase mediator of TGF β signal transduction. J Biol Chem. 1997;272(36):22771–22775. doi: 10.1074/jbc.272.36.22771
   PubMed Web of Science ®Google Scholar
• Sawasdikosol S, Russo KM, Burakoff SJ. Hematopoietic progenitor kinase 1 (HPK1) negatively regulates prostaglandin E2–induced fos gene transcription. Blood. 2003;101(9):3687–3689. doi: 10.1182/blood-2002-07-2316
   PubMed Web of Science ®Google Scholar
• Alzabin S, Bhardwaj N, Kiefer F, et al. Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation. J Immunol. 2009;182(10):6187–6194. doi: 10.4049/jimmunol.0802631
   PubMed Web of Science ®Google Scholar
• Bartolo VD, Montagne B, Salek M, et al. A novel pathway down-modulating T cell activation involves HPK-1-dependent recruitment of 14-3-3 proteins on SLP-76. J Exp Med. 2007;204(3):681–691. doi: 10.1084/jem.20062066
   PubMed Web of Science ®Google Scholar
• Lasserre R, Cuche C, Blecher-Gonen R, et al. Release of serine/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation. J Cell Bio. 2011;195(5):839–853. doi: 10.1083/jcb.201103105
   PubMed Web of Science ®Google Scholar
• Hwang JR, Byeon Y, Kim D, et al. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp Mol Med. 2020;52(5):750–761. doi: 10.1038/s12276-020-0435-8
   PubMed Web of Science ®Google Scholar
• Wang X, Li JP, Kuo HK, et al. Down-regulation of B cell receptor signaling by hematopoietic progenitor kinase 1 (HPK1)-mediated phosphorylation and ubiquitination of activated B cell linker protein (BLNK). J Biol Chem. 2012;287(14):11037–11048. doi: 10.1074/jbc.M111.310946
   PubMed Web of Science ®Google Scholar
• Tsuji S, Okamoto M, Yamada K, et al. B cell adaptor containing src homology 2 domain (BASH) links B cell receptor signaling to the activation of hematopoietic progenitor kinase 1. J Exp Med. 2001;194(4):529–539. doi: 10.1084/jem.194.4.529
   PubMed Web of Science ®Google Scholar
• Soini L, Leysen S, Davis J, et al. A biophysical and structural analysis of the interaction of BLNK with 14-3-3 protein. J Struct Biol. 2020;212(3):107662. doi: 10.1016/j.jsb.2020.107662
   PubMed Web of Science ®Google Scholar
• Rao KMM. MAP kinase activation in macrophages. J Leukocyte Biol. 2001;69(1):3–10. doi: 10.1189/jlb.69.1.3.
   PubMed Web of Science ®Google Scholar
• Bhide RS, Keon A, Weigelt C, et al. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett. 2017;27(21):4908–4913. doi: 10.1016/j.bmcl.2017.09.029.
   PubMed Web of Science ®Google Scholar
• Lee J, Jo S, Lim K, et al. Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods of using same. Patent WO2022064459. 2022.
   Google Scholar
• Chen Y, Liu C, Lv M, et al. High activity HPK1 kinase inhibitor. Patent WO2022089398. 2022.
   Google Scholar
• Deng XM, Huang W, Zhang JM, et al. HPK1 kinase modulator, preparation method therefor, and application thereof. Patent WO2022100688. 2022.
   Google Scholar
• Zhou FS, Zhao JC, He W, et al. Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof. Patent WO2022184152. 2022.
   Google Scholar
• Zhao JC, Zhou FS, Lin CL, et al. Fused ring-substituted six-membered heterocyclic compound, and preparation method therefor and use thereof. Patent WO2023131122. 2023.
   Google Scholar
• Liu B. Tricyclic HPK1 inhibitor and use thereof. Patent WO2022188823. 2022.
   Google Scholar
• Wang ZY, Shao YQ, Li LT, et al. Heterocyclic compounds as HPK1 inhibitors. Patent WO2022188735. 2022.
   Google Scholar
• Bucher C, Dukes A, Gomez B, et al. 1H-pyrazolo[3,4-d] pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (HPK1) modulators and/or inhibitors for the treatment of cancer and other diseases. Patent WO2022197641. 2022.
   Google Scholar
• Al-Awar R, Isaac M, Joseph B, et al. Substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (HPK1). Patent WO2022226666. 2022.
   Google Scholar
• Al-Awar R, Isaac M, Joseph B, et al. Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (HPK1). Patent WO2022226667. 2022.
   Google Scholar
• Chau A, Isaac M, Joseph B, et al. Halo-substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (HPK1). Patent WO2022226665. 2022.
   Google Scholar
• Chau A, Isaac M, Joseph B, et al. Halo-substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (HPK1). Patent WO2022226668. 2022.
   Google Scholar
• Fang H, Yang H. Heterocyclic compounds useful as HPK1 inhibitors. Patent WO2022253252. 2022.
   Google Scholar
• Xie Y, Liu WZ, Qian LQ. Fused ring compound as HPK1 inhibitor. Patent WO2023083282. 2022.
   Google Scholar
• Xie Y, Liu WZ, Qian LQ. Fused ring compounds serving as HPK1 inhibitors. Patent WO2023134608. 2023.
   Google Scholar
• Zhang C, Zhao C, Chai JL, et al. Fused heterocyclic derivative and use thereof in medicine. Patent WO2023109902. 2023.
   Google Scholar
• Zhai WQ, Guo LB, Huang MH, et al. Pyrrole fused-ring pyrazole compound, and preparation method therefor and use thereof. Patent WO2023131271. 2023.
   Google Scholar
• Sun YK, Quan WG, Ma WP, et al. Heteroaryl compounds as HPK1 inhibitors and methods of using same. Patent WO2023137406. 2023.
   Google Scholar
• Fang HQ, Liu XL, Yang H, et al. Heterocyclic compounds useful as HPK1 inhibitors. Patent WO2023138612. 2023.
   Google Scholar
• Liu L, Liu Y, Zhou F, et al. Pyrrolopyridine compound and application thereof. Patent CN114685490. 2022.
   Google Scholar
• Tang F, Hu ZL, Huang LC, et al. Lactam compound as HPK1 inhibitor and application thereof. Patent CN116023378. 2023.
   Google Scholar
• Hu ZL, Liu LF, Tang F, et al. Heterocyclic compound as HPK1 inhibitor and application thereof. Patent CN116265470. 2023.
   Google Scholar
• Jiang S, Xiao YB, Zhou LX, et al. Compound used as HPK1 kinase inhibitor and preparation method and application thereof. Patent CN114853730. 2022.
   Google Scholar
• Zhang KJ, Mao J, Tang H, et al. Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof. Patent CN115873018. 2022.
   Google Scholar
• Wang TY, Xiao YB, Jiang S, et al. Compound of hematopoietic progenitor cell kinase 1 inhibitor and preparation method and application thereof. Patent CN116143779. 2023.
   Google Scholar
• Wu YC, Liu X, Zhong QF, et al. Heterocyclic compound as well as preparation method, pharmaceutical composition and application thereof. Patent CN114907374. 2022.
   Google Scholar
• Li X, Dong HD, Shen F, et al. Condensed bicyclic compound, preparation method thereof and application of fused bicyclic compound in medicine. Patent CN115073472. 2022.
   Google Scholar
• Wu H, Zhang J, Wu WM, et al. HPK1 inhibitor and application thereof in medicine. Patent CN115197132. 2022.
   Google Scholar
• Wu H, Wu WM, Zhang J, et al. HPK1 inhibitor and application thereof in medicine. Patent CN115894480. 2023.
   Google Scholar
• Wu H, Wu WM, Zhang J, et al. HPK1 inhibitor and application thereof in medicine. Patent CN116102550. 2023.
   Google Scholar
• Wu H, Liu QS, Kuang CW, et al. HPK1 inhibitor and application thereof in medicine. Patent CN116332904. 2022.
   Google Scholar
• Zhang XJ, Chang SH, Li XQ, et al. HPK1 inhibitor and application thereof. Patent CN115433184. 2022.
   Google Scholar
• Zhang HC, Jia W, Cai CC. Heterocyclic compounds as HPK1 inhibitors. Patent CN115536656. 2022.
   Google Scholar
• Jia LQ, You ZJ, Ran MS, et al. Heterocyclic lactam compound, pharmaceutical composition containing heterocyclic lactam compound and application of heterocyclic lactam compound. Patent CN115557946. 2023.
   Google Scholar
• Liu B. HPK1 inhibitors and uses thereof. Patent CN115611925. 2023.
   Google Scholar
• Qiu HB, Shen DG, Chen AH, et al. Heterocyclic lactam derivative, preparation method thereof and application of pharmaceutical composition containing derivative in medicine. Patent CN115806553. 2023.
   Google Scholar
• Sun GL, Fang SY, Wang RN, et al. HPK1 inhibitor, preparation method and application thereof. Patent CN116063329. 2023.
   Google Scholar
• Zhang A, Geng MY, Ai J, et al. Novel kinase inhibitor with dimethyl isoindolone structure as well as preparation method and application of novel kinase inhibitor. Patent CN116217561. 2023.
   Google Scholar
• Zhang A, Geng MY, Ai J, et al. HPK1 inhibitor with five-membered aromatic heterocyclic piperidine/homopiperidine and preparation method and application thereof. Patent CN116535422. 2023.
   Google Scholar
• The inventor has waived the right to be mentioned. Anti-tumor compound and application thereof. Patent. CN116462680. 2023.
   Google Scholar
• Papadopoulos PP, Laurie SA, Spira A, et al. TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subject with advanced solid malignancies. J Immunother Cancer. 2023;11(Suppl1):A1–A1731.
   PubMedGoogle Scholar
• Starodub A, Henry J, Vandross A, et al. A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024 in subjects with advanced solid tumors. J Immunother Cancer. 2023;11(Suppl1):A1–A1731.
   PubMedGoogle Scholar
• Sommerhalder D, Noel M, Boiko S, et al. Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor. J Immunother Cancer. 2023;11(Suppl1):A1–A1731.
   PubMedGoogle Scholar
• Li K, Crews CM. PROTACs: past, present and future. Chem Soc Rev. 2022;51(12):5214–5236. doi: 10.1039/D2CS00193D
   PubMed Web of Science ®Google Scholar
• Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181–200. doi: 10.1038/s41573-021-00371-6
   PubMed Web of Science ®Google Scholar
• Gao H, Sun X, Rao Y. PROTAC technology: opportunities and challenge. ACS Med Chem Lett. 2020;11(3):237–240. doi: 10.1021/acsmedchemlett.9b00597
   PubMed Web of Science ®Google Scholar
• Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade. JAMA Oncol. 2019;5(8):1195–1204. doi: 10.1001/jamaoncol.2019.1549
   PubMed Web of Science ®Google Scholar
• Peterson C, Denlinger N, Yang YP. Recent advances and challenges in cancer immunotherapy. Cancers (Basel). 2022;14(16):3972. doi: 10.3390/cancers14163972
   PubMed Web of Science ®Google Scholar
• Yang L, Zhao QL, Chen T, et al. An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma. Clin Exp Med. 2023;23(7):3767–3780. doi: 10.1007/s10238-023-01068-3
   PubMed Web of Science ®Google Scholar
• Schreiber SL. The rise of molecular glues. Cell. 2021;184(1):3–9. doi: 10.1016/j.cell.2020.12.020
   PubMed Web of Science ®Google Scholar
• Dong G, Ding Y, He S, et al. Molecular glues for targeted protein degradation: from serendipity to rational discovery. J Med Chem. 2021;64(15):10606–10620. doi: 10.1021/acs.jmedchem.1c00895
   PubMed Web of Science ®Google Scholar
• Dumontet C, Reichert JM, Senter PD, et al. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641–661. doi: 10.1038/s41573-023-00709-2
   PubMed Web of Science ®Google Scholar
• Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327–344. doi: 10.1038/s41571-021-00470-8
   PubMed Web of Science ®Google Scholar
• Models for immuno-oncology research. Cancer Cell. 2020;38(2):145–147. doi: 10.1016/j.ccell.2020.07.010
   PubMed Web of Science ®Google Scholar
• Dranoff G. Experimental mouse tumour models: what can be learnt about human cancer immunology. Nat Rev Immunol. 2011;12(1):61–66. doi: 10.1038/nri3129
   PubMed Web of Science ®Google Scholar